• ArcticZymes’ third-quarter 2026 net profit fell 50% to NOK 1.4 million, while sales revenue rose 15% to NOK 32.9 million.
• First-nine-month EBITDA more than tripled year-on-year to NOK 12.1 million, while sales revenue climbed 23% to NOK 96.6 million.
• Third-quarter Biomanufacturing sales revenue jumped 44% year-on-year to NOK 18.8 million.
• The company launched its first two enzymes for manufacturing and quality control of RNA-based medicines on October 27.
• The board asked management to evaluate a potential share buyback and using treasury shares for future acquisitions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArcticZymes Technologies ASA published the original content used to generate this news brief via Cision (Ref. ID: 202611050100BITN____UKPR__EN_20261104-BIT-4952-0) on November 05, 2026, and is solely responsible for the information contained therein.